Loading...
Market
Most adopted vaccine by immunocompromised populations in 2024?
2
Resolution / Starting Odds
GeoVax COVID-19 vaccine • 33%
Moderna mRNA influenza vaccine • 33%
Pfizer COVID-19 vaccine • 33%
Healthcare data, CDC reports, medical journals
Story
GeoVax and Moderna Receive $45M and $176M BARDA Funding for Vaccine Development
Jul 2, 2024, 11:02 AM
GeoVax Labs has advanced its COVID-19 vaccine development with up to $45 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). The funding is part of BARDA's Project NextGen initiative, which has a total of $4.7 billion at its disposal. So far, BARDA has awarded approximately 55% of this amount, with nearly $1.9 billion allocated to new COVID-19 vaccines. Since 2023, BARDA has awarded $2.58 billion in grants, with 73% of the funding directed towards vaccine development. BARDA Director Gary Disbrow highlighted the focus on immunocompromised populations. Additionally, Moderna has received $176 million from the US government to accelerate the development of a pandemic influenza mRNA vaccine, amid concerns over bird flu.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
mRNA vaccines • 25%
Non-mRNA vaccines • 25%
No specific recommendation • 25%
Other vaccine types • 25%
Prevention of hospitalization • 25%
Employer or insurance requirements • 25%
Public health campaigns • 25%
Other • 25%
Pfizer-BioNTech • 25%
Moderna • 25%
Novavax • 25%
Other • 25%
Yes • 50%
No • 50%
Moderna • 25%
Pfizer/BioNTech • 25%
Novavax • 25%
Other • 25%
Yes • 50%
No • 50%
Novavax • 25%
Moderna • 25%
Pfizer • 25%
Other • 25%
mRNA vaccines • 25%
Novavax • 25%
Janssen • 25%
Other • 25%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%